Heading to CPhI Worldwide 2025! The Pharmaceutical Technology Center leads a delegation of 20 domestic pharmaceutical manufacturers to explore international cooperation and export opportunities.




The world’s largest pharmaceutical supply chain event—the Convention on Pharmaceutical Ingredients (CPHI)—concluded successfully on October 30. This year’s edition, themed "Shaping the Future Pharma," featured a "Taiwan Pavilion" organized by the Pharmaceutical Industry Technology and Development Center (PITDC) under the banner of the Taiwan Pharmaceutical Alliance (TPA). With support from government initiatives, the pavilion showcased nearly 20 prominent Taiwanese companies—including pharmaceutical manufacturers, contract research organizations (CROs), and packaging suppliers—highlighting Taiwan’s comprehensive pharmaceutical capabilities and supply chain competitiveness. Participating companies this year included: Chung Mei, China Chemical & Pharmaceutical (CCPC), PuraPharm, Swiss Pharmaceutical, United Biomedical (UBI), Standard Chem. & Pharm., Yuan Chou, Yung Shin, Synmosa, OEP, Ming Sheng Biotech, Da-Feng Pharmaceutical, SynCore, Ta-Hsieh, Shintong, Sheng-Tai, Chien-Yi, Pan-Globe, and ScinoPharm, among others.




The Pharmaceutical Industry Technology and Development Center (PITDC) stated that, in order to increase the visibility of Taiwan’s pharmaceutical industry this year, it implemented additional promotional displays, enhanced its website, and launched targeted event marketing. By becoming a "CPHI Key Partner," the center successfully attracted a significant number of visitors. The PITDC noted that, given the intensifying competition in the generic drug market, shifts in U.S. tariff policies, and the ongoing restructuring of global supply chains, it took a proactive approach during this exhibition by facilitating intensive business meetings for TPA (Taiwan Pharmaceutical Alliance) members. These discussions focused on product lines with growing global demand—such as highly complex formulations, emerging targeted therapies, antibody-drug conjugates (ADCs), and PD-1/PD-L1 inhibitors—exploring potential R&D and market collaborations. Furthermore, the center and its members engaged with international industry players to discuss joint drug registration, generic drug licensing, CDMO/CMO (Contract Development and Manufacturing Organization/Contract Manufacturing Organization) partnerships, and strategies for entering new markets.



Starting in 2030, a number of original (branded) drugs worldwide will see their patents expire. By leveraging international trade exhibitions to establish partnerships in advance and seizing the right moment to enter the market, Taiwanese companies can strengthen the export competitiveness of their generic drugs and elevate Taiwan’s role within the global pharmaceutical supply chain. Since its inception in Frankfurt in 1990, CPHI has evolved into a core platform for exchange and supply chain collaboration within the global pharmaceutical industry. It encompasses eight key sectors—including active pharmaceutical ingredients (APIs), finished dosage forms, pharmaceutical packaging, equipment and engineering, as well as CRO and CDMO services—and attracts over 280,000 international professionals annually.



Germany has long been renowned for its high-precision industrial manufacturing, robust R&D capabilities, and clear, strategically driven government policies, making it a vital hub for global pharmaceutical technology collaboration and export operations. This year’s exhibition features new dedicated zones for AI-driven pharmaceutical technology, cold chain and logistics supply chains, and cleanroom manufacturing equipment—reflecting the global pharmaceutical industry’s accelerating shift toward integrated supply chains characterized by automation, high quality, and strict regulatory compliance. Looking ahead, the Pharmaceutical Technology Center will continue to deepen its global market presence and actively foster the integration of Taiwan’s pharmaceutical sector with international markets. By accelerating technological innovation and industrial upgrading, the Center aims to enhance the international competitiveness of Taiwanese pharmaceutical companies. Simultaneously, it will focus on refining export strategies to promote the long-term development of Taiwan’s pharmaceutical industry in the global marketplace, ensuring optimal export outcomes.


Related Attachments

— Share —